tradingkey.logo

TherapeuticsMD Inc

TXMD
View Detailed Chart
1.180USD
+0.010+0.85%
Market hours ETQuotes delayed by 15 min
13.66MMarket Cap
LossP/E TTM

TherapeuticsMD Inc

1.180
+0.010+0.85%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.85%

5 Days

-5.60%

1 Month

+10.04%

6 Months

-16.90%

Year to Date

+37.21%

1 Year

-23.87%

View Detailed Chart

TradingKey Stock Score of TherapeuticsMD Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TherapeuticsMD Inc's Score

Industry at a Glance

Industry Ranking
122 / 159
Overall Ranking
376 / 4616
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

TherapeuticsMD Inc Highlights

StrengthsRisks
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.76M.
Undervalued
The company’s latest PE is -29.41, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.26M shares, decreasing 39.21% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.90K shares of this stock.

TherapeuticsMD Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

TherapeuticsMD Inc Info

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Ticker SymbolTXMD
CompanyTherapeuticsMD Inc
CEOMr. Marlan D. Walker, J.D.
Websitehttps://www.therapeuticsmd.com/
KeyAI